Professional
Added to YB: 2024-09-05
Pitch date: 2024-07-11
NTRA [bullish]
Natera, Inc.
+105.58%
current return
Author Info
No bio for this author
Company Info
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Market Cap
$28.2B
Pitch Price
$111.10
Price Target
N/A
Dividend
N/A
EV/EBITDA
-91.38
P/E
-89.19
EV/Sales
12.92
Sector
Biotechnology
Category
growth
Columbia Acorn Fund Portfolio Holding: Natera, Inc.
NTRA trimmed position: Leading genomic diagnostics co, top in prenatal screening & early in cancer recurrence monitoring. Strong Q1 results. 2024 inflection point w/ multiple clinical data catalysts. Upside potential despite recent gains. Position trimmed for risk management.
Read full article (1 min)